Pediatric Endocrine Society Statement on Considerations for Use of Teplizumab (Tzield™) in Clinical Practice
Recommendations
As issued by the authors
Considerations on all aspects of teplizumab administration, using evidence where possible and a spectrum of expert opinions on unknown aspects
Patient selection and prescreening, highlighting safety and monitoring and treatment of side effects
A proposed schedule of events, a protocol for administration, and practice management aspects
Further long-term systematic surveillance studies are needed to continue evaluating efficacy and safety of teplizumab
Original publication
Pediatric Endocrine Society Statement on Considerations for Use of Teplizumab (Tzield™) in Clinical Practice. Horm Res Paediatr. Published 30 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →